• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

辅助化疗与 21 基因复发评分≥26 的早期乳腺癌患者总生存的关系。

Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher.

机构信息

Department of Radiation Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, New York.

Department of Radiation Oncology, Massachusetts General Hospital, Boston.

出版信息

JAMA Netw Open. 2020 May 1;3(5):e203876. doi: 10.1001/jamanetworkopen.2020.3876.

DOI:10.1001/jamanetworkopen.2020.3876
PMID:32364592
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7199111/
Abstract

This cohort study investigates the association of overall survival with receiving chemotherapy among patients with early-stage breast cancer and recurrence scores of 26 to 30 vs those with recurrence scores of 31 or greater.

摘要

这项队列研究调查了早期乳腺癌患者中，总生存与接受化疗之间的关联，其中复发评分在 26 至 30 分之间的患者与复发评分在 31 分或更高的患者相比。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6db/7199111/ae3d15c83d06/jamanetwopen-3-e203876-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6db/7199111/ae3d15c83d06/jamanetwopen-3-e203876-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/f6db/7199111/ae3d15c83d06/jamanetwopen-3-e203876-g001.jpg

相似文献

1
Association of Adjuvant Chemotherapy With Overall Survival in Patients With Early-Stage Breast Cancer and 21-Gene Recurrence Scores of 26 or Higher.辅助化疗与 21 基因复发评分≥26 的早期乳腺癌患者总生存的关系。
JAMA Netw Open. 2020 May 1;3(5):e203876. doi: 10.1001/jamanetworkopen.2020.3876.
2
Practice patterns and outcomes for patients with node-negative hormone receptor-positive breast cancer and intermediate 21-gene Recurrence Scores.淋巴结阴性激素受体阳性乳腺癌且中间 21 基因复发评分患者的治疗模式和结局。
Breast Cancer Res. 2018 Apr 16;20(1):26. doi: 10.1186/s13058-018-0957-3.
3
21-gene recurrence score and adjuvant chemotherapy decisions in patients with invasive lobular breast cancer.21 基因复发评分与浸润性小叶乳腺癌患者的辅助化疗决策。
Biomark Med. 2019 Feb;13(2):83-93. doi: 10.2217/bmm-2018-0396. Epub 2018 Dec 19.
4
Subtype-Specific Metagene-Based Prediction of Outcome after Neoadjuvant and Adjuvant Treatment in Breast Cancer.基于亚类特异的综合基因预测乳腺癌新辅助和辅助治疗后的预后。
Clin Cancer Res. 2016 Jan 15;22(2):337-45. doi: 10.1158/1078-0432.CCR-15-0757. Epub 2015 Sep 30.
5
Ten years of using adjuvant trastuzumab in breast cancer in Serbia - Single institution experience.塞尔维亚十年辅助性曲妥珠单抗治疗乳腺癌——单机构经验
J BUON. 2018 Mar-Apr;23(2):353-360.
6
Using the 21-gene assay to guide adjuvant chemotherapy decision-making in early-stage breast cancer: a cost-effectiveness evaluation in the German setting.采用 21 基因检测指导早期乳腺癌辅助化疗决策：德国环境下的成本效益评估。
J Med Econ. 2013;16(1):30-40. doi: 10.3111/13696998.2012.722572. Epub 2012 Sep 11.
7
Effect of neoadjuvant chemotherapy regimen on relapse-free survival among patients with breast cancer achieving a pathologic complete response: an early step in the de-escalation of neoadjuvant chemotherapy.新辅助化疗方案对病理完全缓解的乳腺癌患者无复发生存率的影响：新辅助化疗降级的早期步骤。
Breast Cancer Res. 2018 Apr 16;20(1):27. doi: 10.1186/s13058-018-0945-7.
8
Impact of 21-Gene Breast Cancer Assay on Treatment Decision for Patients with T1-T3, N0-N1, Estrogen Receptor-Positive/Human Epidermal Growth Receptor 2-Negative Breast Cancer: Final Results of the Prospective Multicenter ROXANE Study.21 基因乳腺癌检测对 T1-T3、N0-N1、雌激素受体阳性/人表皮生长因子受体 2 阴性乳腺癌患者治疗决策的影响：前瞻性多中心 ROXANE 研究的最终结果。
Oncologist. 2019 Nov;24(11):1424-1431. doi: 10.1634/theoncologist.2019-0103. Epub 2019 May 31.
9
Adjuvant trastuzumab for 6 months is effective in patients with HER2-positive stage II or III breast cancer.辅助性曲妥珠单抗治疗6个月对HER2阳性的II期或III期乳腺癌患者有效。
Asian Pac J Cancer Prev. 2013;14(3):1981-4. doi: 10.7314/apjcp.2013.14.3.1981.
10
The impact of a genomic assay (Oncotype DX) on adjuvant treatment recommendations in early breast cancer.基因组分析（Oncotype DX）对早期乳腺癌辅助治疗建议的影响。
Med J Aust. 2013 Aug 5;199(3):205-8. doi: 10.5694/mja12.11334.

引用本文的文献

1
Association of Neighborhood-Level Household Income With 21-Gene Recurrence Score and Survival Among Patients With Estrogen Receptor-Positive Breast Cancer.社区家庭收入与雌激素受体阳性乳腺癌患者 21 基因复发评分和生存的关系。
JAMA Netw Open. 2023 Feb 1;6(2):e230179. doi: 10.1001/jamanetworkopen.2023.0179.

本文引用的文献

1
Clinical Outcomes in Early Breast Cancer With a High 21-Gene Recurrence Score of 26 to 100 Assigned to Adjuvant Chemotherapy Plus Endocrine Therapy: A Secondary Analysis of the TAILORx Randomized Clinical Trial.21 基因复发评分在 26 到 100 之间的早期乳腺癌患者接受辅助化疗加内分泌治疗的临床结局：TAILORx 随机临床试验的二次分析。
JAMA Oncol. 2020 Mar 1;6(3):367-374. doi: 10.1001/jamaoncol.2019.4794.
2
The Propensity Score.倾向评分
JAMA. 2015 Oct 20;314(15):1637-8. doi: 10.1001/jama.2015.13480.
3
Exploring the burden of inpatient readmissions after major cancer surgery.
探索重大癌症手术后住院再入院的负担。
J Clin Oncol. 2015 Feb 10;33(5):455-64. doi: 10.1200/JCO.2014.55.5938. Epub 2014 Dec 29.
4
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.基因表达与化疗对淋巴结阴性、雌激素受体阳性乳腺癌女性患者的益处。
J Clin Oncol. 2006 Aug 10;24(23):3726-34. doi: 10.1200/JCO.2005.04.7985. Epub 2006 May 23.